Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B
dc.contributor.author | Fung, Scott K. | en_US |
dc.contributor.author | Wong, F. | en_US |
dc.contributor.author | Hussain, Maha H. A. | en_US |
dc.contributor.author | Lok, Anna Suk-Fong | en_US |
dc.date.accessioned | 2010-06-01T19:44:55Z | |
dc.date.available | 2010-06-01T19:44:55Z | |
dc.date.issued | 2004-09 | en_US |
dc.identifier.citation | Fung, S. K.; Wong, F.; Hussain, M.; Lok, A. S. F. (2004). "Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B." Journal of Viral Hepatitis 11(5): 432-438. <http://hdl.handle.net/2027.42/72882> | en_US |
dc.identifier.issn | 1352-0504 | en_US |
dc.identifier.issn | 1365-2893 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/72882 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15357648&dopt=citation | en_US |
dc.format.extent | 124728 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Science Ltd | en_US |
dc.rights | 2004 Blackwell Publishing Ltd | en_US |
dc.subject.other | HBV Core Promoter Mutation | en_US |
dc.subject.other | HBV Precore Mutation | en_US |
dc.subject.other | Hepatitis B Virus Genotypes | en_US |
dc.subject.other | Lamivudine Resistance | en_US |
dc.title | Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | Department of Medicine, University of Toronto, Toronto, Ont., Canada | en_US |
dc.identifier.pmid | 15357648 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/72882/1/j.1365-2893.2004.00556.x.pdf | |
dc.identifier.doi | 10.1111/j.1365-2893.2004.00556.x | en_US |
dc.identifier.source | Journal of Viral Hepatitis | en_US |
dc.identifier.citedreference | Lok AS, Heathcote EJ, Hoofnagle JH. Management of Hepatitis B 2000, Summary of a Workshop. Gastroenterology 2001; 120: 1828 – 1853. | en_US |
dc.identifier.citedreference | Brunetto MR, Oliveri F, Rocca G et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 1989; 10: 198 – 202. | en_US |
dc.identifier.citedreference | Laras A, Koskinas J, Avgidis K, Hadziyannis SJ. Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients. J Viral Hepatitis 1998; 5: 241 – 248. | en_US |
dc.identifier.citedreference | Naoumov NV, Schneider R, Grotzinger T et al. Precore mutant hepatitis B virus infection and liver disease. Gastroenterology 1992; 102: 538 – 543. | en_US |
dc.identifier.citedreference | Grandjacques C, Pradat P, Stuyver L et al. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatology 2000; 33: 430 – 439. | en_US |
dc.identifier.citedreference | Chu CM, Yeh CT, Chiu CT, Sheen IS, Liaw YF. Precore mutant of hepatitis B virus prevails in acute and chronic infections in an area in which hepatitis B is endemic. J Clin Microbiol 1996; 34: 1815 – 1818. | en_US |
dc.identifier.citedreference | Carman WF, Jacyna MR, Hadziyannis S et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588 – 591. | en_US |
dc.identifier.citedreference | Kramvis A, Kew MC, Bukofzer S. Hepatitis B virus precore mutants in serum and liver of South African blacks with hepatocellular carcinoma. J Hepatology 1998; 28: 132 – 141. | en_US |
dc.identifier.citedreference | Funk M, Rosenberg D, Lok A. Worldwide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepatitis 2002; 9: 52 – 61. | en_US |
dc.identifier.citedreference | Chan HLY, Leung NWY, Hussain M, Wong ML, Lok ASF. Hepatitis B e antigen–negative chronic hepatitis B in Hong Kong. Hepatology 2000; 31: 763 – 768. | en_US |
dc.identifier.citedreference | Okamoto H, Tsuda F, Akahane Y et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 1994; 68: 8102 – 8110. | en_US |
dc.identifier.citedreference | Lindh M, Andersson A, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus – large scale analysis using a new genotyping method. J Infect Dis 1997; 175: 1285 – 1293. | en_US |
dc.identifier.citedreference | Chu C, Hussain M, Lok A. Hepatitis B virus genotype B is associated with earlier spontaneous seroconversion than hepatitis B virus genotype C. Gastroenterology 2002; 122: 1756 – 1762. | en_US |
dc.identifier.citedreference | Lai CL, Chien RN, Leung NW et al. A one year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Eng J Med 1998; 339: 61 – 68. | en_US |
dc.identifier.citedreference | Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States. N Engl J Med 1999; 341: 1256 – 1263. | en_US |
dc.identifier.citedreference | Sanantonio T, Mazzola M, Iacovazzi T et al. Long term follow-up of patients with anti- HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatology 2000; 32: 300 – 306. | en_US |
dc.identifier.citedreference | Buti M, Cotrina M, Jardi R et al. 2 years of continuous lamivudine in anti-HBe-positive patients with chronic hepatitis B. J Viral Hepatitis 2001; 8: 270 – 275. | en_US |
dc.identifier.citedreference | Tassopoulos NC, Volpes R, Pastore G et al. Efficacy of lamivudine in chronic hepatitis B with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999; 29: 889 – 896. | en_US |
dc.identifier.citedreference | Hadziyannis, SJ, Papatheodoridis GV, Dimou, E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32:847 – 851. | en_US |
dc.identifier.citedreference | Rizzetto M, Volpes R, Smedile A. Response of pre-core mutant chronic hepatitis B infection to lamivudine. J Med Virol 2000; 61: 398 – 400. | en_US |
dc.identifier.citedreference | Tassopoulos NC, Volpes R, Pastore G et al. Post lamivudine treatment follow-up of patients with HBeAg-negative chronic hepatitis B (abstract). J Hepatology 1999; 30 ( suppl 1 ): 117. | en_US |
dc.identifier.citedreference | Lok ASF, Hussain M, Cursano C et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000; 32:1145 – 1153. | en_US |
dc.identifier.citedreference | Schalm SW, Heathcote J, Cianciara J et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46: 562 – 568. | en_US |
dc.identifier.citedreference | Papatheodoridis G, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis S. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36: 219 – 226. | en_US |
dc.identifier.citedreference | Bedossa P, Poynard T. for the METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289 – 293. | en_US |
dc.identifier.citedreference | Pawlotsky J. Molecular diagnosis of viral hepatitis. Gastroenterology 2002; 122: 1554 – 1568. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.